PSA as a screening test for prostate cancer

Area of Science:

• Oncology
• Urology
• Diagnostic Medicine

Background:

• Prostate cancer incidence is rising, necessitating improved screening strategies.
• Effective early detection methods are essential to reduce prostate cancer mortality.
• Current screening lacks sufficient sensitivity and specificity for widespread use.

Purpose of the Study:

• To evaluate the effectiveness of prostate-specific antigen (PSA) in conjunction with other diagnostic methods for prostate cancer screening.
• To identify optimal procedures for early prostate cancer detection to reduce mortality rates.

Main Methods:

• Utilizing prostate-specific antigen (PSA) blood tests.
• Incorporating digital rectal examination (DRE) as a screening tool.
• Employing transrectal ultrasound (TRUS) for enhanced imaging and detection.

Main Results:

• Prostate-specific antigen (PSA) alone demonstrates insufficient sensitivity and specificity for reliable prostate cancer screening.
• The combination of PSA testing, DRE, and TRUS significantly enhances the detection rates of prostate cancer.
• Integrated diagnostic approaches improve the accuracy of early prostate cancer identification.

Conclusions:

• Prostate-specific antigen (PSA) is a valuable biomarker but requires combination with other methods for effective prostate cancer screening.
• Digital rectal examination (DRE) and transrectal ultrasound (TRUS) are vital components in a multi-modal approach to early prostate cancer detection.
• Establishing standardized screening protocols incorporating PSA, DRE, and TRUS is critical for reducing prostate cancer mortality.